by DealForma Analysts | Jun 20, 2019 | Analysis, Funding, M&A, Partnership Deals
Analysis | Funding | M&A | Partnership Deals Gene therapy deals, R&D partnerships, and acquisitions have been showing annual gains through 2018 and are on track to keep up the record in 2019. The recent approval of Novartis’ Zolgensma gene therapy for...
by DealForma Analysts | Jun 13, 2019 | Analysis, M&A
Analysis | M&A Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and changes the ticker symbol....
by DealForma Analysts | Jan 22, 2019 | Analysis, Funding
Analysis | Funding Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also very active in venture round participation....
by DealForma Analysts | Sep 4, 2018 | Analysis, Partnership Deals
Analysis | Partnership Deals Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to filter for deals involving major R&D and...
